Trial Profile
SINGLE-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO5285119 IN HEALTHY MALE SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2019
Price :
$35
*
At a glance
- Drugs Balovaptan (Primary)
- Indications Autistic disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 04 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jul 2014 New trial record